id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1998-D-0035-0011,FDA,FDA-1998-D-0035,Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments,Other,Guidance,2004-06-22T04:00:00Z,2004,6,,,2024-11-07T21:53:53Z,,1,0,0900006480565951
FDA-1998-D-0035-0014,FDA,FDA-1998-D-0035,FDA,Notice,NAD-Notice of Availability of Data,2004-06-22T04:00:00Z,2004,6,2004-06-21T04:00:00Z,2005-06-22T03:59:59Z,2008-05-16T21:18:11Z,,0,0,0900006480565959
FDA-1998-D-0035-0012,FDA,FDA-1998-D-0035,Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications,Other,Guidance,2004-06-22T04:00:00Z,2004,6,,,2024-11-07T21:53:53Z,,1,0,0900006480565954
FDA-1998-D-0035-0013,FDA,FDA-1998-D-0035,"Guidance for Industry Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis and Interpretation of Clinical Studies",Other,Guidance,2004-06-22T04:00:00Z,2004,6,,,2024-11-07T21:53:53Z,,1,0,0900006480565956